# Methodological and Pathophysiological Considerations in Obesity-Associated Thrombosis

**Authors:** Julia Gniewek, Sebastian Krych, Marta Stępień-Słodkowska, Maria Adamczyk, Tomasz Hrapkowicz, Paweł Kowalczyk

PMC · DOI: 10.3390/ijms27041955 · International Journal of Molecular Sciences · 2026-02-18

## TL;DR

Obesity increases blood clot risk through oxidative stress, and a new system called T-TAS helps assess clotting in a more realistic way.

## Contribution

Introduces T-TAS, a microfluidic system for evaluating thrombus formation under flow, combined with oxidative stress biomarkers for obesity-related thrombosis risk.

## Key findings

- Obesity causes oxidative stress and pro-inflammatory changes that lead to a prothrombotic state.
- T-TAS provides a more accurate assessment of thrombus formation by simulating physiological flow conditions.
- Combining T-TAS with oxidative stress markers improves risk evaluation for obesity-associated thrombosis.

## Abstract

Obesity is a major risk factor for both venous and arterial thrombosis, largely mediated by chronic oxidative stress and hemostatic dysregulation. Excess adipose tissue enhances the production of reactive oxygen species (ROS) from adipocytes and infiltrating macrophages, leading to lipid, protein, and DNA oxidation, reduced antioxidant capacity, and a pro-inflammatory milieu. These molecular alterations promote endothelial dysfunction, platelet hyperreactivity, hypercoagulability, and impaired fibrinolysis, creating a systemic prothrombotic state. Traditional coagulation assays provide limited insight into the dynamic process of thrombus formation under physiological flow. The Total Thrombus-Formation Analysis System (T-TAS) offers a microfluidic, flow-based platform that evaluates thrombus formation in whole blood under controlled shear conditions using collagen- or tissue factor-coated chips. T-TAS parameters, such as time to occlusion, area under the curve (AUC), and pressure kinetics, integrate platelet function, coagulation, and thrombus stability, providing a sensitive assessment of prothrombotic phenotypes. Combining oxidative stress biomarkers (e.g., malondialdehyde, 8-hydroxy-2′-deoxyguanosine, and total antioxidant capacity) with T-TAS-derived functional readouts enables a multidimensional evaluation of thrombosis risk in obese individuals. This review highlights current evidence linking obesity-induced oxidative stress to hemostatic disturbances and illustrates the translational potential of the T-TAS for mechanistic studies and clinical risk stratification. Understanding the interplay between redox imbalance and thrombus formation under flow conditions may inform novel therapeutic strategies to prevent obesity-related thromboembolic events.

## Linked entities

- **Chemicals:** malondialdehyde (PubChem CID 10964), 8-hydroxy-2′-deoxyguanosine (PubChem CID 135406132)
- **Diseases:** obesity (MONDO:0011122), thrombosis (MONDO:0000831)

## Full-text entities

- **Genes:** THAS (thoracoabdominal syndrome) [NCBI Gene 7055] {aka TAS}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CAT (catalase) [NCBI Gene 847], F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, TRAP [NCBI Gene 100187907], P2RY12 (purinergic receptor P2Y12) [NCBI Gene 64805] {aka ADPG-R, BDPLT8, HORK3, P2T(AC), P2Y(12)R, P2Y(AC)}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}, COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** venous and arterial thrombosis (MESH:D020246), dehydration (MESH:D003681), weight loss (MESH:D015431), insulin resistance (MESH:D007333), impaired fibrinolysis (MESH:D060825), myocardial infarction (MESH:D009203), cardiovascular and metabolic diseases (MESH:D002318), blood coagulation (MESH:D001778), thrombocytopenia (MESH:D013921), diabetes (MESH:D003920), Endothelial Dysfunction (MESH:D014652), COVID-19 (MESH:D000086382), ischemic stroke (MESH:D002544), hemostatic (MESH:D020141), venous thromboembolism (MESH:D054556), arterial thrombosis (MESH:D002341), atherosclerosis (MESH:D050197), injury (MESH:D014947), chronic inflammation (MESH:D007249), muscle damage (MESH:D009133), and platelet dysfunction (MESH:D001791), T-TAS (MESH:D013927), cardiometabolic and thrombotic diseases (MESH:D024821), critical illness (MESH:D016638), endothelial (MESH:D005642), sepsis (MESH:D018805), hypoxia (MESH:D000860), metabolic dysregulation (MESH:D021081), metabolic disease (MESH:D008659), Glanzmann thrombasthenia (MESH:D013915), impaired primary hemostasis (MESH:D000081207), fatigue (MESH:D005221), cardiovascular and thromboembolic diseases (MESH:D013923), functional (MESH:D003291), ROTEM (MESH:D009759), Hypercoagulability (MESH:D019851), overweight (MESH:D050177), impaired pulmonary function (OMIM:608852), weight gain (MESH:D015430), bleeding (MESH:D006470), Obesity (MESH:D009765), adiposity (MESH:D018205)
- **Chemicals:** ADP (MESH:D000244), MDA (MESH:D008315), NO2 (MESH:D009585), dabigatran (MESH:D000069604), vitamin E (MESH:D014810), F2-isoprostanes (MESH:D028441), O3 (MESH:D010126), AA (-), Clopidogrel (MESH:D000077144), T (MESH:D014316), 8-OHdG (MESH:D000080242), NO (MESH:D009569), calcium (MESH:D002118), ROS (MESH:D017382), TBARSs (MESH:D017392), vitamin C (MESH:D001205), N-acetylcysteine (MESH:D000111), prostacyclin (MESH:D011464), arachidonic acid (MESH:D016718), lipid (MESH:D008055), thromboxane A2 (MESH:D013928), Aspirin (MESH:D001241), polyphenols (MESH:D059808), carotenoids (MESH:D002338)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941351/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941351/full.md

## References

83 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941351/full.md

---
Source: https://tomesphere.com/paper/PMC12941351